Current status in the discovery of dual BET/HDAC inhibitors

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Oncology

Background:

• Bromodomain and Extra-Terminal domain (BET) and Histone Deacetylase (HDAC) proteins are key epigenetic regulators implicated in cancer.
• Single-target inhibitors for BET and HDAC show therapeutic potential but can be limited.
• BET and HDAC inhibitors exhibit synergistic effects in cancer cells.

Purpose of the Study:

• To review the development of dual BET/HDAC inhibitors.
• To highlight structure-activity relationships (SARs), binding modes, and biological functions of these inhibitors.
• To guide the rational design of novel dual BET/HDAC inhibitors for improved cancer therapy.

Main Methods:

• Literature review of existing studies on dual BET/HDAC inhibitors.
• Analysis of SAR data to understand molecular interactions.
• Examination of binding modes through structural biology insights.
• Evaluation of biological functions and therapeutic potential in cancer models.

Main Results:

• Dual BET/HDAC inhibitors demonstrate enhanced anti-cancer activity compared to single-target agents.
• Specific structural modifications influence inhibitor potency and selectivity.
• Synergistic mechanisms involve coordinated epigenetic modulation.
• Promising preclinical data supports the therapeutic potential of these dual inhibitors.

Conclusions:

• Dual BET/HDAC inhibitors represent a rational and effective approach to cancer treatment.
• Further research into SARs and binding modes will optimize inhibitor design.
• These multitarget agents offer a cost-effective alternative or complement to combination therapies.